eligibility_summary
Eligible: Adults (≥18) with grade 1–3a follicular lymphoma or marginal zone lymphoma, untreated or relapsed/refractory, who began otuzumab between Jun 2021–Apr 2023. Exclude: those in or planning interventional trials, or deemed unsuitable by the investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05968001 is a prospective, multicenter observational study in China assessing real‑world efficacy/safety of obinutuzumab-containing regimens in indolent B‑cell NHL (follicular lymphoma grade 1–3a, marginal zone lymphoma). Two age cohorts: <60 and ≥60 years. Drug/interventions: Obinutuzumab—type II, glycoengineered humanized anti‑CD20 monoclonal antibody, mechanisms: binds CD20 on B cells to induce direct cell death and enhanced ADCC/ADCP (some CDC), depleting malignant/normal B cells. Given in GB, G‑CHOP, or G‑CVP: bendamustine (alkylating DNA crosslinker), cyclophosphamide (alkylator), doxorubicin (topo II inhibitor), vincristine (microtubule inhibitor), prednisone (glucocorticoid). Targets/pathways: CD20+ B cells, immune effector cytotoxicity, DNA damage response, microtubules, topoisomerase II, glucocorticoid-mediated apoptosis.